RGC is Regencell Bioscience Holdings Limited (Healthcare) — a non-dividend-paying stock. Trading at $6.89. Market cap: $3.41B. Capital Quality Rank: 83/100 — Elite compounder.
Stock snapshot
| Price | $6.89 |
| Market cap | $3.41B |
| Sector | Healthcare |
| Exchange | NCM |
| Pays dividend | No |
Capital Quality & fundamentals
DiviDrip's Capital Analytics engine ranks every non-dividend stock 1-100 on a 4-factor composite (Shareholder Yield 30%, Cash-Flow ROI 25%, Operating Momentum 25%, Tail-Risk 20%) — sector-neutralized so a biotech isn't penalized for negative earnings the way a utility would be.
| Capital Quality Rank (1-100) | 83 / 100 · Elite compounder |
| ROIC (TTM) | -91.3% |
| Shareholder buyback yield | 0.00% |
| Altman Z-score zone | Safe |
About RGC
Regencell Bioscience Holdings Ltd is a bioscience company focusing on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people's immune systems.
Frequently asked
What is RGC's current stock price?
RGC (Regencell Bioscience Holdings Limited) is currently trading at $6.89.
Does RGC pay a dividend?
RGC (Regencell Bioscience Holdings Limited) does not currently pay a regular dividend.
What is RGC's Capital Quality Rank?
RGC has a Capital Quality Rank of 83/100 — Elite compounder. This score blends ROIC, revenue growth, buybacks, and balance-sheet health.
Track RGC in DiviDrip
Add RGC to your watchlist on DiviDrip to monitor price, fundamentals, and Capital Quality Rank week-over-week. Built for long-term investors tracking both dividend and non-dividend names.
- Open DiviDrip — search RGC and add it to your watchlist.
- Stock Screener — filter by sector, market cap, and Capital Quality Rank.
- How to use the Screener — sector / quality / market-cap filters explained.
Data refreshed 2026-09-05. Not investment advice. Prices change continuously; always verify the latest numbers in the live app before buying.